AtaiBeckley Inc. 4

COO Gerd Kochendoerfer had 2,075,000 stock options and 150,000 RSUs in AtaiBeckley Inc. cancelled and cashed out at the $6.75 per share merger price plus CVRs in connection with the Eli Lilly acquisition.

On September 11, 2026, in connection with the closing of Eli Lilly and Company’s acquisition of AtaiBeckley Inc., Chief Operating Officer Gerd Kochendoerfer’s equity awards were terminated and cashed out: two tranches of stock options covering 1,400,000 shares at a $1.60 exercise price and 675,000 shares at a $3.76 exercise price, and 150,000 restricted stock units, were all automatically cancelled and converted into the right to receive cash based on the $6.75 per share merger price plus contingent value rights (CVRs) tied to future clinical and regulatory milestones, resulting in no remaining company equity ownership reported post‑transaction.

Filing Facts

CIK

2081043

Ticker

ATAI

Form

4

Source Type

fda

Accession

0001140361-26-036391

Alert Tier

6